Huang J, Zhao D, Liu Z, Liu F. Repurposing psychiatric drugs as anti-cancer agents. Cancer Lett. 2018;419:257–65. https://doi.org/10.1016/j.canlet.2018.01.058.

Article  CAS  PubMed  Google Scholar 

Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58. https://doi.org/10.1038/nrd.2018.168.

Article  CAS  PubMed  Google Scholar 

Badran A, Tul-Wahab A, Zafar H, Mohammad N, Imad R, Ashfaq Khan M, Baydoun E, Choudhary MI. Antipsychotics drug Aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. PLoS ONE. 2020;15(8):e0235676. https://doi.org/10.1371/journal.pone.0235676.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Preti A, Wilson DR. Schizophrenia, cancer and obstetric complications in an evolutionary perspective-an empirically based hypothesis. Psychiatry Invest. 2011;8(2):77–88. https://doi.org/10.4306/pi.2011.8.2.77.

Article  Google Scholar 

Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D. Reduced cancer incidence among patients with schizophrenia. Cancer. 2005;104(12):2817–21. https://doi.org/10.1002/cncr.21574.

Article  PubMed  Google Scholar 

Cohen M, Dembling B, Schorling J. The association between schizophrenia and cancer: a population-based mortality study. Schizophr Res. 2002;57(2–3):139–46. https://doi.org/10.1016/s0920-9964(01)00308-5.

Article  PubMed  Google Scholar 

Wootten JC, Wiener JC, Blanchette PS, Anderson KK. Cancer incidence and stage at diagnosis among people with psychotic disorders: systematic review and meta-analysis. Cancer Epidemiol. 2022;80:102233. https://doi.org/10.1016/j.canep.2022.102233.

Article  PubMed  Google Scholar 

Vlachos N, Lampros M, Voulgaris S, Alexiou GA. Repurposing antipsychotics for Cancer treatment. Biomedicines. 2021;9(12):1785. https://doi.org/10.3390/biomedicines9121785.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masuda T, Tsuruda Y, Matsumoto Y, Uchida H, Nakayama KI, Mimori K. Drug repositioning in cancer: the current situation in Japan. Cancer Sci. 2020;111(4):1039–46. https://doi.org/10.1111/cas.14318.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3(4):495–500.

CAS  PubMed  PubMed Central  Google Scholar 

You F, Zhang C, Liu X, Ji D, Zhang T, Yu R, Gao S. Drug repositioning: using psychotropic drugs for the treatment of glioma. Cancer Lett. 2022;527:140–9. https://doi.org/10.1016/j.canlet.2021.12.014.

Article  CAS  PubMed  Google Scholar 

Matteoni S, Matarrese P, Ascione B, Buccarelli M, Ricci-Vitiani L, Pallini R, Villani V, Pace A, Paggi MG, Abbruzzese C. Anticancer properties of the antipsychotic drug chlorpromazine and its synergism with Temozolomide in restraining human glioblastoma proliferation in vitro. Front Oncol. 2021;11:635472. https://doi.org/10.3389/fonc.2021.635472.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi JH, Yang YR, Lee SK, Kim SH, Kim YH, Cha JY, Oh SW, Ha JR, Ryu SH, Suh PG. Potential Inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival. Ann N Y Acad Sci. 2008;1138:393–403. https://doi.org/10.1196/annals.1414.041.

Article  CAS  PubMed  Google Scholar 

Mehta RD, Roth AJ. Psychiatric considerations in the oncology setting. Cancer J Clin. 2015;65(4):300–14. https://doi.org/10.3322/caac.21285.

Article  Google Scholar 

Xu F, Xi H, Liao M, Zhang Y, Ma H, Wu M, Xue Q, Sun H, Zhang Y, Xia Y. Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy. Cancer Chemother Pharmacol. 2022;89(3):331–46. https://doi.org/10.1007/s00280-021-04386-z.

Article  CAS  PubMed  Google Scholar 

Cui Y, Wu H, Yang L, Huang T, Li J, Gong X, Li L, Sun X, Mao F, Wang Y. Chlorpromazine sensitizes Progestin-Resistant endometrial Cancer cells to MPA by upregulating PRB. Front Oncol. 2021;11:665832. https://doi.org/10.3389/fonc.2021.665832.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan MM, Chen R, Fong D. Targeting cancer stem cells with dietary phytochemical- repositioned drug combinations. Cancer Lett. 2018;433:53–64. https://doi.org/10.1016/j.canlet.2018.06.034.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng HW, Liang YH, Kuo YL, Chuu CP, Lin CY, Lee MH, Wu AT, Yeh CT, Chen EI, Whang-Peng J, Su CL, Huang CY. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data. Cell Death Dis. 2015;6(5):e1753. https://doi.org/10.1038/cddis.2015.77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen J, Ma B, Zhang X, Sun X, Han J, Wang Y, Chu L, Xu H, Yang Y. Thioridazine has potent antitumor effects on lung cancer stem-like cells. Oncol Lett. 2017;13(3):1563–8. https://doi.org/10.3892/ol.2017.5651.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ, Rho SB. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012;17(9):989–97. https://doi.org/10.1007/s10495-012-0717-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arguello PA, Gogos JA. A signaling pathway AKTing up in schizophrenia. J Clin Investig. 2008;118(6):2018–21. https://doi.org/10.1172/JCI35931.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rho SB, Kim BR, Kang S. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3’-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011;120(1):121–7. https://doi.org/10.1016/j.ygyno.2010.10.003.

Article  CAS  PubMed  Google Scholar 

Mu J, Xu H, Yang Y, Huang W, Xiao J, Li M, Tan Z, Ding Q, Zhang L, Lu J, Wu X, Liu Y. Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol Rep. 2014;31(5):2107–14. https://doi.org/10.3892/or.2014.3068.

Article  CAS  PubMed  Google Scholar 

Zhang C, Gong P, Liu P, Zhou N, Zhou Y, Wang Y. Thioridazine elicits potent antitumor effects in colorectal cancer stem cells. Oncol Rep. 2017;37(2):1168–74. https://doi.org/10.3892/or.2016.5313.

Article  CAS  PubMed  Google Scholar 

Song Y, Li L, Chen J, Chen H, Cui B, Feng Y, Zhang P, Zhang Q, Xia Y, Luo M. Thioridazine hydrochloride: an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0/G1 arrest and apoptosis. Cell Cycle. 2020;19(24):3521–33.

CAS  PubMed  PubMed Central  Google Scholar 

Meng Q, Sun X, Wang J, Wang Y, Wang L. The important application of thioridazine in the endometrial cancer. Am J Transl Res. 2016;8(6):2767–75.

CAS  PubMed  PubMed Central  Google Scholar 

Aslostovar L, Boyd AL, Almakadi M, Collins TJ, Leong DP, Tirona RG, Kim RB, Julian JA, Xenocostas A, Leber B, Levine MN, Foley R, Bhatia M. A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Adv. 2018;2(15):1935–45. https://doi.org/10.1182/bloodadvances.2018015677.

Article  CAS  PubMed  PubMed Central